The short answer on PT-141
PT-141 is the development code for bremelanotide, a synthetic peptide built from an alpha-MSH analogue. It activates melanocortin receptors. The compound reached the market in 2019 as Vyleesi, a prescription injection for one narrow group of patients.
What PT-141 is. PT-141 is the research designation for bremelanotide, a synthetic cyclic peptide that activates melanocortin receptors in the central nervous system. The FDA approved it in 2019 as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Research-use material sold under the name PT-141 is a separate category.
The strongest efficacy evidence comes from two identical Phase 3 trials reported in one paper. Desire scores rose 0.5 to 0.6 points on a scale running 1.2 to 6.0, against 0.2 on placebo. Both results reached statistical significance. The size of the change is modest, and saying so is not a criticism of the trials.
Nausea is the safety finding that dominates everything else. It affected 40.0% of treated patients against 1.3% on placebo.
One boundary runs through this whole page. Clinical results describe an approved pharmaceutical product, tested to a defined standard and reviewed by a regulator. No evidence establishes that a research-use material shares that product's formulation, purity, sterility, stability or biological activity.
*Last updated October 15, 2026. This review checked the RECONNECT primary publication, the Phase 2b responder analysis, the two published male trials, the current Vyleesi prescribing information on DailyMed, NCATS drug records, and five FDA warning letters signed August 24, 2026. Prepared by the PrimeTime BioLabs editorial team. A named medical reviewer has not yet been assigned.*
PT-141 at a glance
- Research designation — PT-141
- Generic name — Bremelanotide
- Approved product — Vyleesi, approved 2019
- Compound class — Synthetic cyclic heptapeptide, alpha-MSH analogue
- Receptor potency order — MC1R, MC4R, MC3R, MC5R, MC2R
- Structure — Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH)
- Molecular formula — C50H68N14O10 (free base)
- Molecular weight — 1025.2 (free base)
- Half-life — About 2.7 hours, range 1.9 to 4.0
- Pivotal programme — Two Phase 3 trials, 1,267 randomised
- Current marketer — Cosette Pharmaceuticals
- Evidence grade, approved use — High for the labelled population
These identifiers describe the compound and come from the approved label. The free base and the acetate salt are separate entities with separate registry numbers, and they are not interchangeable. CAS numbers are left out of the table above because this review could not verify them against a primary chemical register. PrimeTime's product listing publishes none of these values, so none of them should be read as a product specification for any particular vial.
Where PT-141 came from
This compound started life as a by-product of tanning research. Melanotan II was the parent, a synthetic melanocortin agonist developed to stimulate pigmentation. PT-141 is described in the pharmacology literature as the deaminated derivative and likely metabolite of MT-II, carrying a free acid at the carboxyl terminus where MT-II carries an amide.
Work on melanocortin agonists kept producing an unexpected observation. Animals given these compounds showed erectile responses. A 2003 paper from Palatin Technologies reported that systemic PT-141 produced erections in rats and nonhuman primates, and activated neurons in the hypothalamus. The same paper reported dose-dependent erectile activity in men.
Palatin built the early programme around an intranasal spray. Both male and female applications were tested by that route, and the doses studied ran far above what the approved product uses today. A single intranasal dose of 20 mg reaches a peak concentration about 2.5 times higher than the approved injection.
Then the blood pressure problem arrived. NCATS records state that intranasal development was temporarily discontinued in 2008, after concerns were raised about increased blood pressure. Secondary sources tell this story inconsistently. Some date the halt to 2007, some to 2008, and they split on whether the FDA stopped it or Palatin did. The NCATS record is the one this page follows, and the disagreement is worth knowing about.
Development moved to subcutaneous injection at a much lower dose. That route gave tighter control over exposure and a smaller blood pressure effect. It is the route that eventually reached approval.
The FDA approved bremelanotide in 2019 under the brand name Vyleesi. Palatin licensed North American rights to AMAG in 2017. The current holder of the application and the current marketer is Cosette Pharmaceuticals, and the label was last revised in March 2024.
One detail from this history carries forward. Both published trials in men used the intranasal route that was abandoned. That shapes how much those results can be made to say.
How PT-141 works
Start with what the label says, because the popular version gets the order wrong. Bremelanotide is described as a melanocortin receptor agonist that nonselectively activates several receptor subtypes. The potency order given is MC1R, MC4R, MC3R, MC5R, MC2R. At therapeutic dose levels, binding to MC1R and MC4R is the most relevant.
How PT-141 works. PT-141 activates melanocortin receptors, with MC1R and MC4R most relevant at therapeutic doses. MC4R neurons sit throughout the central nervous system, including brain regions involved in sexual response. MC1R sits on melanocytes, where activation increases pigment. The label states that the mechanism producing the clinical effect is unknown.
The word nonselective matters. This is not a targeted MC4R compound, and describing it that way overstates what the pharmacology shows. It touches five receptor subtypes with differing potency.
Now the honest part. The label states directly that the mechanism by which the drug improves low sexual desire is unknown. Receptor binding is well characterised. The path from that binding to a change in how someone feels is not. Everything explaining why this compound might work is mechanistic interpretation, which is the weakest evidence grade used on this page.
What distinguishes it from erectile drugs is still real. PDE5 inhibitors act on the nitric oxide pathway in penile blood vessels, improving the physical response. Melanocortin activation happens in the brain. These are separate systems, and the distinction holds even though the downstream steps are unclear.
Two questions come up constantly and deserve direct answers.
Does it raise dopamine? Competitor pages state this as established fact. The approved label makes no dopamine claim. Some published pharmacology discusses melanocortin and dopamine interaction in animal models. No human trial demonstrates that a dopamine increase explains the clinical result. Evidence status: mechanistic interpretation.
Does it raise testosterone? No. Neither the label nor the trial literature reports a testosterone effect. The compound was studied against desire and distress questionnaire scores, and hormone levels were not the endpoint.
MC1R deserves one more mention before moving on. Activation there leads to melanin expression and increased pigmentation. That is the same receptor sitting at the top of the potency list, and it explains why skin darkening appears later as a labelled warning.
What the RECONNECT trials actually found
RECONNECT is two trials reported in one paper. Kingsberg and colleagues published both in Obstetrics and Gynecology in 2019, covering studies registered as NCT02333071 and NCT02338960. Pages referring to a second RECONNECT publication are describing secondary analyses, not a second trial.
Method note. Each figure below was checked against the primary publication and the current prescribing information. Where a value appears only inside a label figure image, the cell reads unverified and no number is supplied. Where a figure circulates widely but belongs to a different study, it is marked and excluded.
Block 1, trial designs
- Trial: RECONNECT Study 301 — Design and phase: Phase 3 randomised, double-blind, placebo-controlled, multicenter — Population: Premenopausal women with acquired, generalized hypoactive sexual desire disorder — Sample size: 628 evaluable for the desire endpoint, 313 on treatment and 315 on placebo — Intervention as reported: Bremelanotide 1.75 mg subcutaneous, as needed, 24 weeks — Comparator: Placebo
- Trial: RECONNECT Study 302 — Design and phase: Phase 3 randomised, double-blind, placebo-controlled, multicenter, identical design — Population: Same criteria as Study 301 — Sample size: 570 evaluable for the desire endpoint, 282 on treatment and 288 on placebo — Intervention as reported: Bremelanotide 1.75 mg subcutaneous, as needed, 24 weeks — Comparator: Placebo
Across both studies, 1,267 women were randomised, 1,247 entered the safety population and 1,202 the efficacy population. The per-study counts above come to slightly less, because a few participants lacked either a baseline or an end-of-study measurement. Mean age was 39 years, with a range of 19 to 56. Participants were 86% White and 12% Black, and 96.6% came from United States sites.
Block 2, results and responder adjudication
- Trial: Study 301 — Co-primary endpoints: Change in FSFI desire domain score, range 1.2 to 6.0; change in FSDS-DAO item 13 score, range 0 to 4 — Responder definition: At least 1.2 point increase in desire; at least 1 point decrease in distress — Responder rates: Unverified, published only as label figure images — Effect size: Desire +0.5 against +0.2 placebo, p=0.0002. Distress -0.7 against -0.4 placebo, p<0.0001
- Trial: Study 302 — Co-primary endpoints: Same two measures — Responder definition: Same thresholds — Responder rates: Unverified, published only as label figure images — Effect size: Desire +0.6 against +0.2 placebo, p<0.0001. Distress -0.7 against -0.4 placebo, p=0.0053
- Trial: Integrated analysis — Co-primary endpoints: Same two measures — Responder definition: Same thresholds — Responder rates: Not reported as percentages in the primary publication — Effect size: Treatment difference +0.35 desire and -0.33 distress, both p<0.001
Evidence status: unverified claim. Responder percentages of roughly 25% against 17% appear across the peptide web as the RECONNECT result. They are not. Responder analyses of that kind were published for the earlier Phase 2b dose-ranging study, a separate trial with a different design. The label does report RECONNECT responder thresholds, but it presents the percentages inside two figure images this review could not read as text. No responder percentage is used anywhere on this page.
Block 3, evidence status and citations
- Trial: Study 301 — Evidence grade: High — Main limitation: 40% of treated patients discontinued before week 24, against 13% on placebo — Citation: Kingsberg SA, et al. Obstet Gynecol. 2019;134(5):899-908. PMID 31599840
- Trial: Study 302 — Evidence grade: High — Main limitation: 39% of treated patients discontinued, against 25% on placebo — Citation: Kingsberg SA, et al. Obstet Gynecol. 2019;134(5):899-908. PMID 31599840
- Trial: Phase 2b responder analysis — Evidence grade: Moderate — Main limitation: Dose-finding study, not a registration trial. Its responder rates are frequently misattributed to RECONNECT — Citation: Althof S, et al. J Sex Med. 2019;16(8):1226-1235. PMID 31277966
What the numbers actually mean
Scale ranges make these results legible, and most coverage leaves them out. The desire score runs from 1.2 to 6.0. Participants started around 2.0 to 2.1 and gained 0.5 to 0.6 points, where placebo gained 0.2. The distress score runs 0 to 4. Participants started near 2.9 and dropped 0.7 points, where placebo dropped 0.4.
Median changes tell the same story. Desire rose 0.6 points on treatment and 0 on placebo. Distress fell 1 point on treatment and 0 on placebo.
Statistical significance and practical magnitude are separate questions. These results clear significance comfortably. The change itself is a fraction of a point on short questionnaires, and whether that matters to a given person is a judgement the numbers cannot make.
The dropout problem nobody reports
Here is the finding absent from every competing page reviewed for this article.
In Study 301, 40% of patients taking bremelanotide left the 24 week double-blind period early. On placebo, 13% did. Study 302 ran 39% against 25%. Across both trials, 18% of treated patients discontinued because of adverse reactions, against 2% on placebo.
The label treats this seriously. It states that because a greater percentage of treated patients discontinued early, an exploratory analysis was performed looking only at patients who completed treatment.
Why this weakens a change-score result is worth spelling out. People who leave a trial early tend to be the ones tolerating it worst or benefiting least. When one arm loses three times as many participants as the other, the groups being compared at the end are no longer the groups that were randomised. The effect is real and it is measured in a population shaped by who stayed.
This does not invalidate the trials. It is a limitation the label itself flags, and it belongs beside the headline numbers.
The endpoint that did not move
Satisfying sexual events were a secondary endpoint, counting actual encounters. Mean change from baseline was 0.0 in both treatment arms and both placebo arms. The p values were 0.76 in Study 301 and 0.70 in Study 302.
Desire scores improved. Distress scores improved. The number of satisfying encounters did not change in either direction. Any claim that this compound produces more sex is unsupported by its own registration trials.
What the research shows for men
The label is explicit. Vyleesi is not indicated for the treatment of low sexual desire in men, and it is not indicated to enhance sexual performance. No Phase 3 programme in men was ever completed.
Two published trials carry the male evidence, and both are smaller and older than the female programme.
Safarinejad and Hosseini, 2008. Published in the Journal of Urology, this randomised 342 married men aged 28 to 59 who had not responded to sildenafil. One group received 10 mg intranasal bremelanotide, the other placebo. Positive clinical results appeared in 51 of 172 treated men, which is 33.5%, against 13 of 170 on placebo, which is 8.5%. The reported p value was 0.03. Treated men also reported greater intercourse satisfaction, and more drug-related adverse effects. Evidence grade: Moderate. Study type: Phase 2 randomised, double-blind, placebo-controlled.
Diamond and colleagues, 2005. Published in Urology, this was a crossover pilot in 19 men with erectile dysfunction who already responded to oral agents. Participants received 25 mg sildenafil with 7.5 mg intranasal PT-141, sildenafil with a placebo spray, or placebo alone. Erectile response measured by RigiScan over six hours was greater with the combination than with sildenafil alone. Evidence grade: Limited. Study type: Randomised crossover pilot.
Two corrections belong here, because both errors are everywhere.
A paper cited as Rosen 2006 appears in reference lists across peptide sites as male bremelanotide evidence. Searches of PubMed did not locate it. Evidence status: unverified claim. It is not used on this page.
A claim that combination therapy increased erectile duration more than fivefold is widely attributed to the Diamond work. That figure does not appear in the published abstract, and this review could not source it. It is not used either.
One limitation governs this entire section. Both trials delivered the compound intranasally, at 10 mg and 7.5 mg. That route was discontinued in 2008 over blood pressure concerns, and the approved product uses 1.75 mg subcutaneously. Neither male trial describes the product that exists today, and neither describes a research-use material.
How PT-141 compares with PDE5 inhibitors
Every comparison page carries a table. Almost none of them mention that no randomised trial has ever compared these compounds directly.
- Site of action — PT-141 (bremelanotide): Central nervous system — PDE5 inhibitors: Penile vascular tissue — Comparability: Direct, mechanisms differ
- Molecular target — PT-141 (bremelanotide): Melanocortin receptors, MC1R and MC4R most relevant — PDE5 inhibitors: Phosphodiesterase type 5 enzyme — Comparability: Direct, unrelated targets
- Studied population — PT-141 (bremelanotide): Premenopausal women with HSDD — PDE5 inhibitors: Men with erectile dysfunction — Comparability: Not comparable, different populations
- Primary endpoints — PT-141 (bremelanotide): Desire and distress questionnaire scores — PDE5 inhibitors: Erectile function scores — Comparability: Not comparable, different measures
- Approved indication — PT-141 (bremelanotide): Acquired generalized HSDD in premenopausal women — PDE5 inhibitors: Erectile dysfunction in men — Comparability: Comparable by regulatory status only
- Most common adverse event — PT-141 (bremelanotide): Nausea, 40.0% — PDE5 inhibitors: Headache, varies by agent — Comparability: Comparable in kind only
- Key contraindication — PT-141 (bremelanotide): Uncontrolled hypertension or known cardiovascular disease — PDE5 inhibitors: Concurrent nitrate use — Comparability: Both cardiovascular, different mechanisms
- Head-to-head trial — PT-141 (bremelanotide): None exists — PDE5 inhibitors: None exists — Comparability: No direct comparison has been run
That last row carries the section. Any statement ranking one compound against the other rests on comparing separate trials, in different populations, measuring different things. Comparison across trials like that is indirect evidence, and it is weaker than a randomised head-to-head result. No such result exists here.
The mechanistic difference is genuine and worth understanding. One compound acts on blood flow in tissue. The other acts on brain signalling. They are not competing approaches to the same step.
On combining them, the published evidence is thin and specific. Diamond and colleagues co-administered subtherapeutic doses to 19 men in a crossover pilot, using the intranasal route. That is what exists. The approved label addresses no PDE5 combination, and this page offers no guidance on combining anything.
PT-141 and Melanotan II, a safety contrast
These two compounds share a family and a chemistry, which is why they get confused. Their regulatory positions could hardly be further apart.
- Structural relationship — PT-141 (bremelanotide): Deaminated derivative and likely metabolite of MT-II — Melanotan II: Parent compound
- Terminal group — PT-141 (bremelanotide): Free acid at the carboxyl terminus — Melanotan II: Amide
- Receptor profile — PT-141 (bremelanotide): Nonselective, MC1R and MC4R most relevant at therapeutic doses — Melanotan II: Nonselective melanocortin agonist
- Principal studied effect — PT-141 (bremelanotide): Sexual desire and arousal — Melanotan II: Pigmentation
- Approved product — PT-141 (bremelanotide): Yes, Vyleesi, 2019 — Melanotan II: None
- Regulatory status — PT-141 (bremelanotide): Prescription drug with a label — Melanotan II: Not approved in the United States
- Pigmentation — PT-141 (bremelanotide): Labelled warning, 1% at labelled frequency — Melanotan II: A primary intended effect
- Evidence base — PT-141 (bremelanotide): Two Phase 3 trials, published label — Melanotan II: No registration programme
One correction belongs here, because the popular version of this comparison is too flattering to PT-141. Writers often describe it as the selective version, targeting desire while leaving pigmentation alone. The label does not support that. Bremelanotide is nonselective, and MC1R sits at the top of its potency list. Pigmentation is a labelled warning for a reason.
What separates them is documentation, not purity of mechanism. One compound went through trials, produced a label, and carries a known adverse event profile with numbers attached. The other did not.
Evidence does not transfer between them in either direction. Results from one say nothing about the other, and that holds for safety as much as for effect.
Side effects and safety, what the trials and label report
Every rate below comes from the pooled Phase 3 placebo-controlled trials, in the approved-product population. The table lists every reaction the label reports in at least 2% of treated patients. None of these rates describes a research vial.
- Nausea — Bremelanotide (n=627): 40.0% — Placebo (n=620): 1.3%
- Flushing — Bremelanotide (n=627): 20.3% — Placebo (n=620): 0.3%
- Injection site reactions — Bremelanotide (n=627): 13.2% — Placebo (n=620): 8.4%
- Headache — Bremelanotide (n=627): 11.3% — Placebo (n=620): 1.9%
- Vomiting — Bremelanotide (n=627): 4.8% — Placebo (n=620): 0.2%
- Cough — Bremelanotide (n=627): 3.3% — Placebo (n=620): 1.3%
- Fatigue — Bremelanotide (n=627): 3.2% — Placebo (n=620): 0.5%
- Hot flush — Bremelanotide (n=627): 2.7% — Placebo (n=620): 0.2%
- Paraesthesia — Bremelanotide (n=627): 2.6% — Placebo (n=620): 0.0%
- Dizziness — Bremelanotide (n=627): 2.2% — Placebo (n=620): 0.5%
- Nasal congestion — Bremelanotide (n=627): 2.1% — Placebo (n=620): 0.5%
The nausea signal
Nausea is the defining tolerability problem, and the numbers around it are specific. It affected 40.0% of treated patients against 1.3% on placebo. Incidence peaked after the first dose at 21%, then fell to roughly 3% with later doses. Median onset came within one hour, lasting about two hours.
Thirteen percent of treated patients needed an anti-emetic. Eight percent left the trials because of it.
One widely repeated piece of advice is wrong. Several pages recommend taking ondansetron beforehand. A Phase 4 study randomised 228 healthy women to 8 mg oral ondansetron or placebo thirty minutes before a dose. No significant difference in nausea appeared between the groups. The label states that pre-treatment with oral ondansetron is not recommended.
Blood pressure and heart rate
Two separate datasets exist here, and merging them produces a misleading picture.
The label's warning section reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking between two and four hours after a dose. Heart rate falls by up to 5 beats per minute. Both return to baseline usually within 12 hours.
A different study measured something else. An open-label ambulatory monitoring study followed 127 premenopausal women taking a dose daily for eight days. Mean daytime increases were 1.9 mmHg systolic and 1.7 mmHg diastolic. Those are averages across a day of monitoring under daily dosing, and they are not the same measurement as the peak figures above.
This effect is why intranasal development stopped in 2008. Higher exposure by that route produced blood pressure changes that ended the programme.
Skin pigmentation
Focal hyperpigmentation appeared in 1% of patients receiving up to eight doses per month, against none on placebo. It affected the face, gums and breasts.
Frequency changes the picture sharply. In a separate study, 38% of patients developed focal hyperpigmentation after eight days of daily dosing. Among those continuing another eight days, a further 14% developed new pigmentary changes. Patients with darker skin were more likely to be affected.
The reversibility question gets treated as open across the peptide web. The label answers it. Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation. That is not a finding of permanence, and it is not reassurance either.
Who the trials excluded and the naltrexone interaction
The label contraindicates use in patients with uncontrolled hypertension or known cardiovascular disease. It is also not recommended for patients at high cardiovascular risk. Safety and effectiveness have not been established in paediatric or geriatric patients.
Exposure increases in renal impairment, roughly doubling in severe cases. Moderate hepatic impairment raises exposure by about 1.7-fold. Severe hepatic impairment was never studied.
Naltrexone is the interaction the label treats most seriously. Bremelanotide may significantly decrease the systemic exposure of orally administered naltrexone. The label advises avoiding the combination with oral naltrexone products used to treat alcohol and opioid addiction, citing the severe consequence of treatment failure.
Gastric emptying slows more generally. That matters for oral drugs depending on threshold concentrations to work, such as antibiotics.
Pregnancy carries its own warning. Animal studies in dogs and mice produced embryofetal toxicity and developmental delays at exposures well above human levels, and no safe dose was established in either species.
What the evidence does not settle
Strong evidence in one place does not mean strong evidence everywhere. Seven questions remain genuinely open.
How it produces the effect. The label states the mechanism is unknown. Receptor binding is characterised. The path from binding to a change in desire is not, and every mechanistic explanation on this page is interpretation.
Whether the effect holds in a stable population. Dropout reached 40% in one arm. Nobody can say from the published data what the change scores would look like in a group that stayed.
What the responder rates were. The label defines the thresholds and publishes the percentages only as figure images. Values circulating online belong to a different trial.
Whether any of it produces more satisfying encounters. The secondary endpoint measuring exactly that found no difference, in both trials.
What happens in men. Two trials, one abandoned route, no Phase 3, no approved indication, and no data on the formulation that exists today.
Whether pigmentation reverses. The label reports that resolution was not confirmed in all patients. That is an open question stated honestly, and it is not the same as saying the change is permanent.
What long-term use does. The controlled period ran 24 weeks. The extension that followed was open-label and uncontrolled. Nothing describes use beyond that.
One further gap deserves naming separately. No evidence establishes that a research-use material sold under this compound name shares the approved product's formulation, purity, sterility, stability or biological activity. Not weak evidence or contested evidence. None. The studies that would establish it have not been done, and that is a statement about what has been tested.
Research material and the approved medicine are not the same thing
Three names describe one chemistry and three different situations.
PT-141 is the development designation, still the term most people search for. Bremelanotide is the generic name and the International Nonproprietary Name, used in regulatory and clinical writing. Vyleesi is the approved prescription product, manufactured to a defined standard and reviewed by the FDA.
What the 2019 approval covers is narrower than most coverage suggests. It applies to premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label explicitly excludes postmenopausal women, excludes men, and excludes use to enhance sexual performance.
What happened in August 2026
This compound sits at the centre of a recent enforcement action, and the detail matters.
Verified. The FDA signed warning letters to five online peptide sellers on August 24, 2026, posting them on September 1. The recipients were Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations trading as Tex Peptides. PT-141 or PT-141 (Bremelanotide) is named in all five letters. Each letter quotes the seller's own product-page wording as evidence that the product was intended for use as a drug.
Interpretation. The quoted language is descriptive. One letter cites a page saying PT-141 targets the central nervous system directly to improve libido and pleasure. Another cites a page describing it as a non-selective agonist of melanocortin receptors with primary activity at MC3R and MC4R. That second phrasing is worth pausing on. It is close to how most of the industry describes this compound, and by the approved label's own ordering it also gets the receptors wrong.
What the letters do not establish. These are enforcement actions about how products were presented. They do not rule on the compound itself, they do not make it illegal, and they do not make it approved. A research-use label is a statement about how something may lawfully be offered, and the FDA reads a seller's whole presentation when deciding what a product is intended for. Our guide to how US law treats research-use labeling covers that framework in detail.
What documentation can and cannot tell you
A certificate of analysis has a real but limited job. It can support identity, meaning the material is the compound it claims to be. It can report purity by a stated analytical method, and content against a stated specification.
Safety sits outside its scope. So does efficacy, and so does correct biological activity, because chemical purity and biological behaviour are separate properties. A purity figure answers a chemistry question. Our guide to how to read a peptide Certificate of Analysis explains what each section means, and how to evaluate a research peptide supplier covers what to ask before ordering anything.
This article contains no dosing, no reconstitution instructions and no administration guidance. That is deliberate.
The bottom line
Bremelanotide has real human evidence behind it, graded high for one narrow approved population. Two Phase 3 trials showed statistically significant improvements in desire and distress scores. The changes were fractions of a point on short questionnaires, roughly 40% of treated patients left the trials early, and the endpoint counting satisfying encounters did not move.
Three things stay unsettled no matter how the numbers are presented. The mechanism producing the effect is unknown by the label's own account. The male evidence rests on two trials using a route abandoned in 2008. And nothing published describes what a research-use material does, because those studies have not been run.
PT-141 supplied by PrimeTime BioLabs is intended for laboratory research only. It is not for human or veterinary use, not for diagnostic or therapeutic application, and not approved by the FDA for any medical purpose. See our PT-141 10 mg research material listing for batch documentation, and our guide to reading a certificate of analysis for what that documentation establishes.
